

Please type a plus sign (+) inside this box



PTO/SB/QRA (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete If Known

Application Number	09/837,562
Filing Date	04/18/2001
First Named Inventor	McCleary, Edward Larry
Group Art Unit	1623
Examiner Name	Travis C McIntosh
Attorney Docket Number	12439.104

RECEIVED
MAY 15 2003
TECH CENTER 1600 2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
(P)	1	TARNOPOLSKY MA, BEAL MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. <i>Ann Neurol</i> . 2001 May; 49(5): 561-74.	
(P)	2	Ferrante RJ, ET AL., Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. <i>J Neurosci</i> . 2000 Jun 15; 20(12): 4389-97.	
(P)	3	MILLER JW ET AL., Homocysteine, vitamin B6, and vascular disease in AD patients. <i>Neurology</i> . 2002 May 28; 58(10): 1471-5.	
(P)	4	DHITAVAT, S. ET AL., Acetyl-L-carnitine protects against amyloid-beta neurotoxicity: roles of oxidative buffering and ATP levels. <i>Neurochem Res</i> . 2002 Jun; 27(6): 501-5.	
(P)	5	LIU J, ET AL., Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. <i>Proc Natl Acad Sci USA</i> . 2002 Feb 19; 99(4): 2356-61.	
(P)	6	GONZALEZ-PEREZ O, ET AL., Beneficial effects of alpha-lipoic acid plus vitamin E on neurological deficit, reactive gliosis and neural remodeling in the penumbra of the ischemic rat brain. <i>Neurosci Lett</i> . 2002 Mar 15; 321(1-2): 100-4.	
(P)	7	BASKAYA MK, ET AL., Neuroprotective effects of citicholine on brain edema and blood-brain barrier breakdown after traumatic brain injury. <i>J Neurosurg</i> . 2000 Mar; 92(3): 448-52.	
(P)	8	RAO AM, ET AL., CDP-choline: neuroprotection in transient forebrain ischemia of gerbils. <i>J Neurosci Res</i> . 1999 Dec 1; 58(5): 697-705.	
(P)	9	CLARO FT, ET AL., Bovine brain phosphatidylserine attenuates scopolamine-induced amnesia. <i>Physiol Behav</i> . 1999 Oct; 67(4): 51-4.	
(P)	10	CHALON S, ET AL., Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. <i>J Nutr</i> . 1998 Dec; 128(12): 2512-9.	
(P)	11	MISCHOULON D, FAVA M., Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. <i>Am J Clin Nutr</i> . 2002 Nov; 76(5): 1158S.	
(P)	12	GENEDANI S, ET AL., Influence of SAME on the modifications of brain polyamine levels in an animal model of depression. <i>Neuroreport</i> . 2001 Dec 21; 12(18): 3939-42.	
(P)	13	PAVIA J, ET AL., Effect of S-adenosylmethionine on muscarinic receptors in young rats. <i>Life Sci</i> . 1997; 60(11): 825-32.	
(P)	14	MCCARTY MF., Prenatal high-dose pyridoxine may prevent hypertension and Syndrome X in-utero by protecting the fetus from excess glucocorticoid activity. <i>Med Hypotheses</i> . 2000 May; 54(5): 808-13.	

Examiner Signature

[Signature]

Date Considered

7/22/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.